Organic Active Ingredients TRIZ Cases

Synthetic BCL11A microRNAs target stem cells to raise fetal hemoglobin in hemoglobinopathies.

This case applies PEG-20k osmotic gradients during CPR to limit cell swelling and improve coronary perfusion and organ function.

This case uses a crush-resistant PEO matrix to extend oral ketamine release and reduce dissociation versus injections.

This case uses linked BRD9-binding and degradation moieties to deplete BRD9 while targeting BAF-related cancers and infections.

This case uses modified wing, gap, and separator segments to improve HBV targeting while reducing antisense toxicity.

Branched triple lipid-modified nucleic acids improve cellular uptake for therapeutic delivery.

This case uses α5-GABAA inverse regulators to address slow onset, gastric instability, and poor solubility in oral antidepressants.

This case uses NPC1 and SOAT1 biomarkers to improve liver cancer diagnosis while inhibitors target cancer cell growth.

This case develops thymine-derived triazolopyrimidines to inhibit cancer proliferation while limiting side effects and rearrangement.

5aa-OGP and CBD work together to accelerate fracture repair and limit osteolysis.

Modular 1,3,4-oxadiazole triazole compounds selectively inhibit HDAC6 to improve bioavailability and reduce class I side effects.

IKZF2 degraders target regulatory T cells to enhance immunity while limiting systemic toxicity.

Substituted tetrahydrofuran analogs target Nav1.8 to support pain therapy.

A homogeneous melt of drugs, waxes, and fatty acids forms microparticles cured for consistent release over six months.

This case uses DHX36 inhibitors to stabilize pathogenic G-quadruplexes and suppress toxic RAN translation in ALS and FTD.

A CSDT device mixes aqueous diluent and antibiotics for convenient, lower-concentration injection into surgical skin or mucosa.

Controlled microfluidics produces uniform moxidectin microparticles that limit burst release and reduce repeated injection discomfort.

Defined substitutions on a diazaspiroheptane core enable selective T-type calcium channel modulation across multiple conditions.

Solvent, anti-solvent, and water-activity controls produce reproducible crystalline API forms for scalable manufacture.

A tromethamine GLP-1R agonist salt improves oral solubility and bioavailability.

This case uses intravenous neuroactive steroids, optionally with cyclodextrin, to modulate brain excitability while limiting sedation.

This case examines a formula-based compound that promotes chondrocyte proliferation and differentiation to support cartilage regeneration.

This case combines placental allograft and hyaluronic acid to enable injection, implant interdigitation, and bone repair.

This case uses localized substituents and linker changes to improve HDAC8 selectivity, inhibit cancer cells, and reduce off-target effects.

Defined XRPD and DSC crystalline forms support stable, bioavailable, and manufacturable tenofovir alafenamide formulations.

Amniotic membrane powder in hydrogel scaffolds supports wound healing while reducing donor-site and immunosuppression limits.

A retinoid-containing five-component LNP combines cellular mRNA delivery with humoral, cellular, and mucosal immune responses.

Targeting moieties bind megalin or cubilin to internalize nucleic acid payloads in kidney cells and reduce off-target effects.

This case uses trisubstituted triazoles to inhibit Rac/Cdc42-PAK signaling, limiting breast cancer cell migration and metastasis.

GNA, FNA, and SNA modifications help recruit ADAR proteins while structured domains improve selectivity and stability for targeted RNA editing.

This skin-protection composition uses a thymol ester to increase DNA repair gene expression against UV and oxidative stress.

This case uses structural and deuterium changes to help quinazolinone BRAF inhibitors cross the blood-brain barrier.

This case uses Child-Pugh dose ranges and titration to balance nalbuphine efficacy with accumulation and adverse events.

Modular heteroaryl and heterocyclic substitutions target METTL3/METTL14 activity while supporting simpler compound synthesis.

Conventional agents may not sufficiently suppress IL-33 and IL-1; this derivative targets their production and gene expression.

This case uses amino-substituted benzamide structures to improve bioavailability and activity against resistant Leishmania and Trypanosoma.

This case uses selective diazabicyclooctane derivatives to inhibit MMP activity, limit cardiac remodeling, and improve heart function.

This case uses low-dose, periodic 5-MeO-DMT inhalation to improve bipolar symptoms while avoiding treatment-emergent mania or hypomania.

This case shows how fused compounds inhibit or degrade IRAK4, addressing its kinase and scaffolding functions to support broader efficacy.

A two-step wound protocol combines ethacridine lactate, zinc oxide, and emollients to support healing while preserving the skin microbiome.

This case uses oral Compound A prodrugs to block TPL2-ERK signaling and reduce cytokine production in inflammatory bowel disease.

Anionic modifiers give polyurethane medical articles antimicrobial and anti-fouling properties while avoiding separate coating steps.

This case links aromatic ring compounds to NNMT and UHRF1 markers, aiming to improve tumor precision while reducing dosage and side effects.

Formula (I) KIF18A inhibitors target chromosomally unstable tumor cells, limiting normal-cell damage from broad anti-mitotic drugs.

This case combines KRAS inhibitors with anti-CTLA-4 or anti-CCR8 agents to target Tregs and improve durable tumor responses.

Equivir combines myricetin and hesperidin to target viral enzymes, downregulate TNF-α, and protect cellular integrity.

This case pairs rAAV-delivered shRNA suppression with resistant RHO replacement to protect photoreceptors from retinal degeneration.

Zn(II) agents trigger PARP-1-driven necrotic-like cancer cell death and stimulate immunity alongside immune-oncology agents.

Pre-metered dry powder formulations deliver antivirals to lung tissue, supporting local bioavailability and limiting systemic side effects.

Allele-specific antisense molecules silence mutant KCNQ1 to reduce LQT1 arrhythmias.

Drpitor1 compounds target Drp1 GTPase to resolve specificity and potency trade-offs in mitochondrial fission inhibition.

Substituted 6-arylamino pyridone carboxamides inhibit MEK enzyme activity through targeted structural modification.

Macrocyclic compounds bind presenter proteins to form complexes that target the intracellular protein CEP250.

A berberine ursodeoxycholate composition reduces serum alkaline phosphatase and hepatocellular inflammation through synergistic anti-inflammatory and cholestatic mechanisms.

Specific chemical compounds inhibit BCRP-mediated efflux transport, restoring anticancer agent effectiveness against resistant tumor cells.

A nalbuphine ester prodrug dissolved in a composite solvent system resolves solubility constraints to achieve an extended release period of up to 14 days.

Telaprevir-derived compounds enhance antiviral potency against EV-D68 while reducing side effects through targeted structural parameter changes.

A pharmaceutical composition combining ciclopirox olamine, malic acid, and sodium borate to treat skin infections.

A selective PERK kinase inhibitor reduces endoplasmic reticulum stress through targeted molecular modification.

Alpha-2C adrenoceptor antagonists maintain upper airway patency through selective receptor modulation, addressing CPAP intolerance in sleep apnea patients.

Nano-in-micro encapsulated siRNA dry powder maintains high bioactive yield while reducing hygroscopicity through nested lipid and sugar structures.

Xloc13 lincRNA overcomes BRAFV600E inhibitor resistance by enabling early diagnosis and enhancing radioiodine uptake in aggressive thyroid cancer.

Buffered fenofibric acid salts eliminate significant food effects and prevent Cmax exceedance through controlled release mechanisms.

Adding N-acetyl-D-mannosamine to culture media increases orexin gene expression, resolving the bottleneck of insufficient orexin-producing cells.

A compound binds filamin A to block mu opioid receptor coupling switches.

Pre-mixed parenteral aprotinin and nirmatrelvir formulation addresses rapid strain mutation by targeting multiple viral lifecycle stages simultaneously.

BMP inhibitors target lipid metabolism pathways to lower cholesterol and triglycerides where conventional therapies fail.

High-purity grape seed extract reduces perceived stress symptoms through targeted oral administration of specific proanthocyanidin and catechin ratios.

A cationized chitosan and sulfated glycosaminoglycan complex neutralizes hemorrhagic activity while preserving wound healing promotion effects.

Propylene carbonate dissolves tacrolimus in an ointment base, preventing chemical decomposition during storage.

A pharmaceutical dosage form uses anisotropic geometry with bulges and indentations to control drug release kinetics.

GSK-3 inhibitor 9-ING-41 overcomes low response rates in microsatellite stable colorectal cancer by sensitizing tumors to alpha PD-1 therapy.

Small molecule Wnt inhibitors mitigate renal fibrosis and vascular inflammation, addressing diabetic nephropathy side effects from systemic glucocorticoids.

Combining sirolimus and nintedanib reduces vascular malformation volume and size in hereditary hemorrhagic telangiectasia.

Small molecule compounds bind to the Y220C pocket of mutant p53 protein to stabilize its structure and restore DNA binding capability.

Indole-3-aldehyde activates the Aryl Hydrocarbon Receptor to modulate immune homeostasis, addressing inflammatory side effects of current treatments.

Effervescent budesonide tablets achieve deep mucosal healing by segmenting induction and maintenance phases to improve esophageal targeting.

A seamless capsule in a tobacco filter releases caryophyllene during inhalation to promote relaxation and sleep.

A new manufacturing process for a monoacylglycerol lipase inhibitor uses controlled crystallization to achieve high yields.

Amphiphilic peptide drug nanoconjugates self-assemble to release doxorubicin via cathepsin B cleavage, reducing toxicity to normal cells.

Whitened beet material absorbs active ingredients to enable controlled release profiles, resolving limited delivery efficiency in smokeless tobacco.

Novel small-molecule GLP-1 receptor agonists overcome poor oral bioavailability of peptide drugs while maintaining high therapeutic efficacy.

Oil-in-water emulsions incorporate cannabinoids into small oil droplets to improve bioavailability while reducing side effects.

Antisense oligonucleotides bind FOXP3 mRNA to inhibit expression, overcoming the lack of surface markers on immunosuppressive Tregs.

Synthesizing shishijimicin analogs overcomes natural rarity to provide reliable anticancer payloads.

Segmenting aqueous and lipid phases enables zero-order release over three days, reducing corticosteroid use for chemotherapy-induced nausea.

Combination pharmaceutical compositions block viral replication and prevent disease progression.

Mastic gum feed composition improves digestion and reduces ammonia levels, minimizing nitrogen excretion to lower nitrate pollution.

pH-dependent delayed release coating manages drug timing to maintain consistent plasma concentration for twelve hours.

An alkaline aqueous polyol solvent stabilizes alpha lipoic acid against acidic degradation, enhancing oral bioavailability.

Co-administering ABL inhibitors with mevalonate pathway blockers impairs mitochondrial function in lung cancer cells.

Agar-derived oligosaccharides kill Staphylococcus without triggering antibiotic resistance mechanisms.

Biaryl compounds inhibit AAK1 activity to treat schizophrenia and Alzheimer's disease.

AI-PRS platform screens drug combinations using regression functions to overcome resistance and improve efficacy.

Piperazine-based modulators target CXCR7 to block SDF-1 binding, resolving specificity limits in cancer therapy.

Inupadenant blocks adenosine receptors to restore T cell activity, reversing immunosuppression in high adenosine tumor microenvironments.

IGF1R antibodies suppress microglial activation and inflammation, resolving inadequate symptom management in neurodegenerative diseases.